{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:14:43Z","timestamp":1771010083137,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jsat.2017.01.004","type":"journal-article","created":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T03:15:20Z","timestamp":1484363720000},"page":"17-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Characterizing fentanyl use in methadone-maintained clients"],"prefix":"10.1016","volume":"75","author":[{"given":"Cynthia L.","family":"Arfken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Suchanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2017.01.004_bb0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12954-015-0088-4","article-title":"Why the FUSS (fentanyl urine screen study)? A cross-sectional survey to characterize an emerging threat to people who use drugs in British Columbia, Canada","volume":"12","author":"Amlani","year":"2015","journal-title":"Harm Reduction Journal"},{"issue":"10","key":"10.1016\/j.jsat.2017.01.004_bb0010","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1001\/jamainternmed.2016.4306","article-title":"Adverse effects from counterfeit alprazolam tablets","volume":"176","author":"Arens","year":"2016","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.jsat.2017.01.004_bb0015","author":"Arfken"},{"key":"10.1016\/j.jsat.2017.01.004_bb0020","author":"Arfken"},{"issue":"1","key":"10.1016\/j.jsat.2017.01.004_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.annemergmed.2016.06.014","article-title":"Fentanyl and a novel synthetic opioid U-47700 masquerading as street \u201cNorco\u201d in Central California: A case report","volume":"69","author":"Armenian","year":"2016","journal-title":"Annals of Emergency Medicine"},{"key":"10.1016\/j.jsat.2017.01.004_bb0030","series-title":"Deaths involving fentanyl in Canada, 2009\u20132014","author":"Canadian Centre on Substance Abuse","year":"2015"},{"key":"10.1016\/j.jsat.2017.01.004_bb0040","article-title":"Increases in fentanyl drug confiscations and fentanyl-related overdose fatalities","author":"Centers for Disease Control and Prevention (CDC)","year":"2015","journal-title":"Health Alert Network"},{"key":"10.1016\/j.jsat.2017.01.004_bb0045","author":"Centers for Disease Control and Prevention, National Center for Health Statistics"},{"key":"10.1016\/j.jsat.2017.01.004_bb0050","author":"Drug Enforcement Administration (DEA)"},{"key":"10.1016\/j.jsat.2017.01.004_bb0055","series-title":"DEA issues nationwide alert on fentanyl as threat to health and public safety","author":"Drug Enforcement Administration (DEA)","year":"2015"},{"key":"10.1016\/j.jsat.2017.01.004_bb0060","author":"Drug Enforcement Administration (DEA)"},{"key":"10.1016\/j.jsat.2017.01.004_bb0065","series-title":"National heroin threat assessment summary","author":"Drug Enforcement Administration (DEA)","year":"2016"},{"key":"10.1016\/j.jsat.2017.01.004_bb0070","author":"European Monitoring Center for Drugs and Drug Addiction (EMCDDA)"},{"issue":"33","key":"10.1016\/j.jsat.2017.01.004_bb0075","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15585\/mmwr.mm6533a2","article-title":"Fentanyl law enforcement submissions and increases in synthetic opioid-involved overdose deaths \u2013 27 states, 2013-2014","volume":"65","author":"Gladden","year":"2016","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"10.1016\/j.jsat.2017.01.004_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2015.01.009","article-title":"Gender-specific predictors of retention and opioid abstinence during methadone maintenance treatment","volume":"54","author":"Levine","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2017.01.004_bb0085","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.drugpo.2015.04.003","article-title":"Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe","volume":"26","author":"Mounteney","year":"2015","journal-title":"The International Journal on Drug Policy"},{"issue":"5","key":"10.1016\/j.jsat.2017.01.004_bb0090","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose deaths \u2013 United States, 2000-2014","volume":"64","author":"Rudd","year":"2016","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"10.1016\/j.jsat.2017.01.004_bb0095","author":"United States Census Bureau"},{"issue":"3","key":"10.1016\/j.jsat.2017.01.004_bb0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid Mu receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regulatory Toxicology and Pharmacology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216304731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216304731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:45:10Z","timestamp":1760039110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216304731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":19,"alternative-id":["S0740547216304731"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.004","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing fentanyl use in methadone-maintained clients","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2017.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}